Revolution Medicines
Presença
Revolution Medicines é uma das ...
Revolution Medicines é uma empresa listada sob o símbolo RVMD (US).
Fusão, aquisição e financiamento envolvendo Revolution Medicines.
- Revolution Medicines adquiriu Eqrx (publicado em 10 de novembro de 2023).
Executivos
Veja o organograma con seus 37 executivos principais
Biografias mais buscadas da Revolution Medicines
- Mark Goldsmith, President, Chief Executive Officer and Board Chair...
- Thilo Schroeder, Director
- Sushil Patel, Director
Criar um alerta
para seguir os movimentos de executivos da Revolution Medicines.
Farmacêutica
Revolution Medicines possui 1.859 concorrentes concorrentes Pfizer (Estados Unidos), Johnson & Johnson (Estados Unidos) e Sanofi (França).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Revolution Medicines
- Press Releases | Revolution Medicines
- Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition | Revolution Medicines
- Revolution Medicines Completes Acquisition of EQRx | Revolution Medicines
- Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress | Revolution Medicines
- Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023 | Revolution Medicines
- Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc. | Revolution Medicines
- Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 | Revolution Medicines
- Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast | Revolution Medicines, Inc.
- Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting | Revolution Medicines, Inc.
- Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor | Revolution Medicines, Inc.
- View more press releases Close
Redes sociais sobre Revolution Medicines
- Revolution Medicines na Wikipedia, Google News e Yahoo Finance
- Revolution Medicines na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Mark Goldsmith 
Ligue para a Revolution Medicines em +1 415...
